NTAGI panel recommends inclusion of Covovax in vaccination drive for 12-17 age group

"The COVID-19 working group of the NTAGI (National Technical Advisory Group on Immunisation) had earlier reviewed data related to Covovax and okayed it. The NTAGI's Standing Technical Sub-Committee which met on Friday has recommended that the vaccine can be used for 12-17 years age group," an official source said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iuDkHIl
via IFTTT